<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00314951</url>
  </required_header>
  <id_info>
    <org_study_id>5119-018</org_study_id>
    <secondary_id>101.1.C.003</secondary_id>
    <nct_id>NCT00314951</nct_id>
  </id_info>
  <brief_title>Fidaxomicin Versus Vancomycin for the Treatment of Clostridium Difficile-Associated Diarrhea (CDAD) (MK-5119-018)</brief_title>
  <official_title>A Multi-National, Multi-Center, Double-Blind, Randomized, Parallel Group Study to Compare the Safety and Efficacy of 200 mg PAR-101 Taken q12h With 125 mg Vancomycin Taken q6h for Ten Days in Subjects With Clostridium Difficile-Associated Diarrhea</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Optimer Pharmaceuticals LLC</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Optimer Pharmaceuticals LLC</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      This is a comparative study to investigate the safety and efficacy of fidaxomicin versus
      vancomycin in subjects with Clostridium difficile-Associated Diarrhea (CDAD).
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      The primary objective of this pivotal study is to investigate the safety and efficacy of
      fidaxomicin versus vancomycin in subjects with Clostridium difficile-associated diarrhea
      (CDAD). The cure rates at end of therapy and recurrence rates will be evaluated and compared.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">May 2, 2006</start_date>
  <completion_date type="Actual">August 21, 2008</completion_date>
  <primary_completion_date type="Actual">July 23, 2008</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Double (Participant, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Cure Rate at End of Therapy</measure>
    <time_frame>Study day 10 (+/- 2 days)</time_frame>
    <description>Percentage of participants with 3 or fewer unformed stools for 2 consecutive days and maintained through the end of therapy, and the subject no longer needed specific anti-Clostridium antibacterial treatment after completion of the course of study medication.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Recurrence</measure>
    <time_frame>Study days 11-40</time_frame>
    <description>Percentage of participants with the re-establishment of diarrhea to an extent(based on frequency of passed unformed stools) that was greater than that noted on the last day of study medication, and the demonstration of either toxin A or B or both of C. difficile, and retreatment with CDI anti-infective therapy was needed.</description>
  </secondary_outcome>
  <other_outcome>
    <measure>Global Cure</measure>
    <time_frame>End of Study (Day 40)</time_frame>
    <description>Percentage of participants who were cured (3 or fewer unformed stools for 2 days through the end of therapy, and no C. difficile therapy after study drug completion) and didn't have recurrence (re-establishment of diarrhea that was greater than on the last day of study drug, positive C. difficile toxin and retreatment with C. difficile therapy) up to Day 40.</description>
  </other_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">629</enrollment>
  <condition>Clostridium Infections</condition>
  <condition>Diarrhea</condition>
  <arm_group>
    <arm_group_label>fidaxomicin</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Participants receiving fidaxomicin 200 mg capsules orally two times daily (every 12 hours [q12h] regimen) with intermittent matching placebo to fidaxomicin</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Vancomycin</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Participants receiving vancomycin 125 mg capsules orally four times daily (every 6 hours [q6h] regimen).</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Fidaxomicin</intervention_name>
    <description>200 mg oral capsules two times daily (q12h regimen)</description>
    <arm_group_label>fidaxomicin</arm_group_label>
    <other_name>PAR-101</other_name>
    <other_name>OPT-80</other_name>
    <other_name>Dificid®</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Vancomycin</intervention_name>
    <description>125 mg capsules q6hr (4 times a day)</description>
    <arm_group_label>Vancomycin</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Matching Placebo to Fidaxomicin</intervention_name>
    <description>Matching Placebo to Fidaxomicin administered two times daily (intermittently with fidaxomicin dosing)</description>
    <arm_group_label>fidaxomicin</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Males/females with CDAD

          -  Females must use adequate contraception

          -  Signed informed consent

        Exclusion Criteria:

          -  Life-threatening CDAD

          -  Toxic megacolon

          -  Pregnant

          -  Concurrent use of diarrheal agents

          -  Participation in other trials
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>16 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Medical Director</last_name>
    <role>Study Director</role>
    <affiliation>Merck Sharp &amp; Dohme Corp.</affiliation>
  </overall_official>
  <removed_countries>
    <country>Canada</country>
    <country>United States</country>
  </removed_countries>
  <results_reference>
    <citation>Louie TJ, Miller MA, Mullane KM, Weiss K, Lentnek A, Golan Y, Gorbach S, Sears P, Shue YK; OPT-80-003 Clinical Study Group. Fidaxomicin versus vancomycin for Clostridium difficile infection. N Engl J Med. 2011 Feb 3;364(5):422-31. doi: 10.1056/NEJMoa0910812.</citation>
    <PMID>21288078</PMID>
  </results_reference>
  <verification_date>March 2017</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>April 13, 2006</study_first_submitted>
  <study_first_submitted_qc>April 13, 2006</study_first_submitted_qc>
  <study_first_posted type="Estimate">April 17, 2006</study_first_posted>
  <results_first_submitted>July 1, 2011</results_first_submitted>
  <results_first_submitted_qc>September 16, 2011</results_first_submitted_qc>
  <results_first_posted type="Estimate">October 26, 2011</results_first_posted>
  <disposition_first_submitted>August 27, 2010</disposition_first_submitted>
  <disposition_first_submitted_qc>August 27, 2010</disposition_first_submitted_qc>
  <disposition_first_posted type="Estimate">August 31, 2010</disposition_first_posted>
  <last_update_submitted>March 23, 2017</last_update_submitted>
  <last_update_submitted_qc>March 23, 2017</last_update_submitted_qc>
  <last_update_posted type="Actual">April 21, 2017</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>CDAD, Clostridium difficile, diarrhea</keyword>
  <keyword>Clostridium difficile-Associated Diarrhea</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Diarrhea</mesh_term>
    <mesh_term>Clostridium Infections</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Vancomycin</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>Yes</sharing_ipd>
    <ipd_description>http://www.merck.com/clinical-trials/pdf/Merck%20Procedure%20on%20Clinical%20Trial%20Data%20Access%20Final_Updated%20July_9_2014.pdf
http://engagezone.msd.com/ds_documentation.php</ipd_description>
  </patient_data>

  <clinical_results>

    <participant_flow>
      <recruitment_details>Subjects were enrolled from May 2006 to August 2008 by centers in the United States and Canada.</recruitment_details>
      <group_list>
        <group group_id="P1">
          <title>Vancomycin</title>
          <description>125 mg administered 4 times daily (q6hr)</description>
        </group>
        <group group_id="P2">
          <title>Fidaxomicin</title>
          <description>200 mg administered twice daily (q12hr)</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Enrollment</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="323"/>
                <participants group_id="P2" count="306"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="323">6 subjects took incorrect treatment assignment, 6 subjects didn't take drug</participants>
                <participants group_id="P2" count="300">6 subjects took incorrect treatment assignment, 6 subjects didn't take drug</participants>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="6"/>
              </participants_list>
            </milestone>
          </milestone_list>
        </period>
        <period>
          <title>Treatment</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="323"/>
                <participants group_id="P2" count="300"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="307"/>
                <participants group_id="P2" count="289"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="16"/>
                <participants group_id="P2" count="11"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>Didn't meet criteria for mITT population</title>
              <participants_list>
                <participants group_id="P1" count="16"/>
                <participants group_id="P2" count="11"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
        <period>
          <title>Follow-up</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="307"/>
                <participants group_id="P2" count="289"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="263"/>
                <participants group_id="P2" count="255"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="44"/>
                <participants group_id="P2" count="34"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>mITT failure</title>
              <participants_list>
                <participants group_id="P1" count="44"/>
                <participants group_id="P2" count="34"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>Vancomycin</title>
          <description>125 mg administered 4 times daily (q6hr)</description>
        </group>
        <group group_id="B2">
          <title>Fidaxomicin</title>
          <description>200 mg administered twice daily (q12hr)</description>
        </group>
        <group group_id="B3">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="307"/>
            <count group_id="B2" value="289"/>
            <count group_id="B3" value="596"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="62.9" spread="16.9"/>
                    <measurement group_id="B2" value="60.3" spread="16.9"/>
                    <measurement group_id="B3" value="61.6" spread="16.9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Sex: Female, Male</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Female</title>
                  <measurement_list>
                    <measurement group_id="B1" value="169"/>
                    <measurement group_id="B2" value="164"/>
                    <measurement group_id="B3" value="333"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Male</title>
                  <measurement_list>
                    <measurement group_id="B1" value="138"/>
                    <measurement group_id="B2" value="125"/>
                    <measurement group_id="B3" value="263"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Region of Enrollment</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>United States</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="186"/>
                    <measurement group_id="B2" value="165"/>
                    <measurement group_id="B3" value="351"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Canada</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="121"/>
                    <measurement group_id="B2" value="124"/>
                    <measurement group_id="B3" value="245"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Cure Rate at End of Therapy</title>
        <description>Percentage of participants with 3 or fewer unformed stools for 2 consecutive days and maintained through the end of therapy, and the subject no longer needed specific anti-Clostridium antibacterial treatment after completion of the course of study medication.</description>
        <time_frame>Study day 10 (+/- 2 days)</time_frame>
        <population>Analysis data is modified intent to treat (mITT) population. The mITT population consists of subjects that had CDAD confirmed by &gt;3 unformed bowel movements in the 24 hours prior to randomization and a positive toxin assay and received at least one dose of study medication.</population>
        <group_list>
          <group group_id="O1">
            <title>Vancomycin</title>
            <description>125 mg administered 4 times daily (q6hr)</description>
          </group>
          <group group_id="O2">
            <title>Fidaxomicin</title>
            <description>200 mg administered twice daily (q12hr)</description>
          </group>
        </group_list>
        <measure>
          <title>Cure Rate at End of Therapy</title>
          <description>Percentage of participants with 3 or fewer unformed stools for 2 consecutive days and maintained through the end of therapy, and the subject no longer needed specific anti-Clostridium antibacterial treatment after completion of the course of study medication.</description>
          <population>Analysis data is modified intent to treat (mITT) population. The mITT population consists of subjects that had CDAD confirmed by &gt;3 unformed bowel movements in the 24 hours prior to randomization and a positive toxin assay and received at least one dose of study medication.</population>
          <units>Percentage of Participants</units>
          <param>Number</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="307"/>
                <count group_id="O2" value="289"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="85.7" lower_limit="81.3" upper_limit="89.2"/>
                    <measurement group_id="O2" value="88.2" lower_limit="84.0" upper_limit="91.5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>H0: C(fidaxomicin) – C(Vancomycin) &lt;= -10% Power calculation is based on cure rate of 85% in both treatment groups, non-inferiority margin of 10%, 2.5% (1-sided) type I error rate with approximately 90% power gives a total of 530 subjects.</groups_desc>
            <non_inferiority_type>Non-Inferiority or Equivalence</non_inferiority_type>
            <non_inferiority_desc>The point estimate of the difference and the 2-sided 95% confidence interval (CI) for the difference between treatment groups were computed. If the lower limit of the CI was greater than -10%, the clinical non-inferiority of fidaxomicin was demonstrated. CIs for the difference of cure rates were calculated using the method recommended by Agresti and Caffo.</non_inferiority_desc>
            <param_type>Risk Difference (RD)</param_type>
            <param_value>2.6</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-2.9</ci_lower_limit>
            <ci_upper_limit>8.0</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Recurrence</title>
        <description>Percentage of participants with the re-establishment of diarrhea to an extent(based on frequency of passed unformed stools) that was greater than that noted on the last day of study medication, and the demonstration of either toxin A or B or both of C. difficile, and retreatment with CDI anti-infective therapy was needed.</description>
        <time_frame>Study days 11-40</time_frame>
        <population>The mITT population for subjects who met the primary endpoint of cure subjects, were analyzed for the recurrence rates of diarrhea up to the Poststudy Visit.</population>
        <group_list>
          <group group_id="O1">
            <title>Vancomycin</title>
            <description>125 mg administered 4 times daily (q6hr)</description>
          </group>
          <group group_id="O2">
            <title>Fidaxomicin</title>
            <description>200 mg administered twice daily (q12hr)</description>
          </group>
        </group_list>
        <measure>
          <title>Recurrence</title>
          <description>Percentage of participants with the re-establishment of diarrhea to an extent(based on frequency of passed unformed stools) that was greater than that noted on the last day of study medication, and the demonstration of either toxin A or B or both of C. difficile, and retreatment with CDI anti-infective therapy was needed.</description>
          <population>The mITT population for subjects who met the primary endpoint of cure subjects, were analyzed for the recurrence rates of diarrhea up to the Poststudy Visit.</population>
          <units>Percentage of Participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="263"/>
                <count group_id="O2" value="255"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="25.1"/>
                    <measurement group_id="O2" value="15.7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.008</p_value>
            <method>Chi-squared</method>
            <param_type>Risk Difference (RD)</param_type>
            <param_value>-9.4</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-16.2</ci_lower_limit>
            <ci_upper_limit>-2.5</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Other Pre-specified</type>
        <title>Global Cure</title>
        <description>Percentage of participants who were cured (3 or fewer unformed stools for 2 days through the end of therapy, and no C. difficile therapy after study drug completion) and didn't have recurrence (re-establishment of diarrhea that was greater than on the last day of study drug, positive C. difficile toxin and retreatment with C. difficile therapy) up to Day 40.</description>
        <time_frame>End of Study (Day 40)</time_frame>
        <population>The analysis population is mITT, subjects that achieved a cure response at end of treatment and not having a recurrence at any time up to the Post-study visit.</population>
        <group_list>
          <group group_id="O1">
            <title>Vancomycin</title>
            <description>125 mg administered 4 times daily (q6hr)</description>
          </group>
          <group group_id="O2">
            <title>Fidaxomicin</title>
            <description>200 mg administered twice daily (q12hr)</description>
          </group>
        </group_list>
        <measure>
          <title>Global Cure</title>
          <description>Percentage of participants who were cured (3 or fewer unformed stools for 2 days through the end of therapy, and no C. difficile therapy after study drug completion) and didn't have recurrence (re-establishment of diarrhea that was greater than on the last day of study drug, positive C. difficile toxin and retreatment with C. difficile therapy) up to Day 40.</description>
          <population>The analysis population is mITT, subjects that achieved a cure response at end of treatment and not having a recurrence at any time up to the Post-study visit.</population>
          <units>Percentage of Participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="307"/>
                <count group_id="O2" value="289"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="64.2"/>
                    <measurement group_id="O2" value="74.4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.007</p_value>
            <method>Chi-squared</method>
            <param_type>Risk Difference (RD)</param_type>
            <param_value>10.2</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>2.8</ci_lower_limit>
            <ci_upper_limit>17.5</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>From Informed consent to 7-days following the last dose of study drug or until the last protocol-specified study visit, whichever occured later.</time_frame>
      <group_list>
        <group group_id="E1">
          <title>Vancomycin</title>
          <description>125 mg administered 4 times daily (q6hr)</description>
        </group>
        <group group_id="E2">
          <title>Fidaxomicin</title>
          <description>200 mg administered twice daily (q12hr)</description>
        </group>
      </group_list>
      <serious_events>
        <default_vocab>MedDRA 10.0</default_vocab>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="78" subjects_at_risk="323"/>
                <counts group_id="E2" subjects_affected="75" subjects_at_risk="300"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Blood and lymphatic system disorders</title>
            <event_list>
              <event>
                <sub_title>Thrombocytopenia</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="323"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="300"/>
              </event>
              <event>
                <sub_title>Anaemia</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="323"/>
                <counts group_id="E2" subjects_affected="4" subjects_at_risk="300"/>
              </event>
              <event>
                <sub_title>Granulocytopenia</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="323"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="300"/>
              </event>
              <event>
                <sub_title>Leukocytosis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="323"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="300"/>
              </event>
              <event>
                <sub_title>Leukopenia</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="323"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="300"/>
              </event>
              <event>
                <sub_title>Lymphadenopathy</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="323"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="300"/>
              </event>
              <event>
                <sub_title>Lymphopenia</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="323"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="300"/>
              </event>
              <event>
                <sub_title>Febrile neutropenia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="323"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="300"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Cardiac disorders</title>
            <event_list>
              <event>
                <sub_title>Cardiac failure congestive</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="323"/>
                <counts group_id="E2" subjects_affected="4" subjects_at_risk="300"/>
              </event>
              <event>
                <sub_title>Cardiogenic shock</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="323"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="300"/>
              </event>
              <event>
                <sub_title>Myocardial infarction</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="323"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="300"/>
              </event>
              <event>
                <sub_title>Atrial fibrillation</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="323"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="300"/>
              </event>
              <event>
                <sub_title>Atrial flutter</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="323"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="300"/>
              </event>
              <event>
                <sub_title>Cardiac arrest</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="323"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="300"/>
              </event>
              <event>
                <sub_title>Cor pulmonale</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="323"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="300"/>
              </event>
              <event>
                <sub_title>Supraventricular tachycardia</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="323"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="300"/>
              </event>
              <event>
                <sub_title>Ventricular tachycardia</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="323"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="300"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Congenital, familial and genetic disorders</title>
            <event_list>
              <event>
                <sub_title>Cleft palate</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="323"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="300"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Diarrhoea</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="323"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="300"/>
              </event>
              <event>
                <sub_title>Large intestine perforation</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="323"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="300"/>
              </event>
              <event>
                <sub_title>Abdominal pain</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="323"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="300"/>
              </event>
              <event>
                <sub_title>Ascites</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="323"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="300"/>
              </event>
              <event>
                <sub_title>Colitis ischaemic</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="323"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="300"/>
              </event>
              <event>
                <sub_title>Gastrointestinal haemorrhage</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="323"/>
                <counts group_id="E2" subjects_affected="4" subjects_at_risk="300"/>
              </event>
              <event>
                <sub_title>Ileus</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="323"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="300"/>
              </event>
              <event>
                <sub_title>Inguinal hernia, obstructive</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="323"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="300"/>
              </event>
              <event>
                <sub_title>Peritonitis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="323"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="300"/>
              </event>
              <event>
                <sub_title>Colitis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="323"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="300"/>
              </event>
              <event>
                <sub_title>Intestinal obstruction</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="323"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="300"/>
              </event>
              <event>
                <sub_title>Megacolon</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="323"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="300"/>
              </event>
              <event>
                <sub_title>Small intestinal obstruction</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="323"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="300"/>
              </event>
              <event>
                <sub_title>Vomiting</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="323"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="300"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>Chest pain</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="323"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="300"/>
              </event>
              <event>
                <sub_title>Malaise</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="323"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="300"/>
              </event>
              <event>
                <sub_title>Pyrexia</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="323"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="300"/>
              </event>
              <event>
                <sub_title>Generalised oedema</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="323"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="300"/>
              </event>
              <event>
                <sub_title>Hypothermia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="323"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="300"/>
              </event>
              <event>
                <sub_title>Impaired healing</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="323"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="300"/>
              </event>
              <event>
                <sub_title>Multi-organ failure</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="323"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="300"/>
              </event>
              <event>
                <sub_title>Oedema peripheral</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="323"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="300"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Hepatobiliary disorders</title>
            <event_list>
              <event>
                <sub_title>Cholecystitis acute</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="323"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="300"/>
              </event>
              <event>
                <sub_title>Cholelithiasis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="323"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="300"/>
              </event>
              <event>
                <sub_title>Liver disorder</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="323"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="300"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Immune system disorders</title>
            <event_list>
              <event>
                <sub_title>Anaphylactic reaction</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="323"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="300"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>Clostridium difficile colitis</sub_title>
                <counts group_id="E1" subjects_affected="6" subjects_at_risk="323"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="300"/>
              </event>
              <event>
                <sub_title>Pneumonia</sub_title>
                <counts group_id="E1" subjects_affected="5" subjects_at_risk="323"/>
                <counts group_id="E2" subjects_affected="4" subjects_at_risk="300"/>
              </event>
              <event>
                <sub_title>Sepsis</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="323"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="300"/>
              </event>
              <event>
                <sub_title>Staphylococcal bacteraemia</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="323"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="300"/>
              </event>
              <event>
                <sub_title>Staphylococcal sepsis</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="323"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="300"/>
              </event>
              <event>
                <sub_title>Urosepsis</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="323"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="300"/>
              </event>
              <event>
                <sub_title>Aspergillosis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="323"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="300"/>
              </event>
              <event>
                <sub_title>Bacteraemia</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="323"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="300"/>
              </event>
              <event>
                <sub_title>Endocarditis bacterial</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="323"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="300"/>
              </event>
              <event>
                <sub_title>Enterocolitis infectious</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="323"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="300"/>
              </event>
              <event>
                <sub_title>Escherichia bacteraemia</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="323"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="300"/>
              </event>
              <event>
                <sub_title>Escherichia sepsis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="323"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="300"/>
              </event>
              <event>
                <sub_title>Meningitis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="323"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="300"/>
              </event>
              <event>
                <sub_title>Postoperative wound infection</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="323"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="300"/>
              </event>
              <event>
                <sub_title>Pseudomonal sepsis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="323"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="300"/>
              </event>
              <event>
                <sub_title>Pyelocystitis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="323"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="300"/>
              </event>
              <event>
                <sub_title>Septic shock</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="323"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="300"/>
              </event>
              <event>
                <sub_title>Systemic candida</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="323"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="300"/>
              </event>
              <event>
                <sub_title>Wound infection staphylococcal</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="323"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="300"/>
              </event>
              <event>
                <sub_title>Abdominal abscess</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="323"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="300"/>
              </event>
              <event>
                <sub_title>Abdominal sepsis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="323"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="300"/>
              </event>
              <event>
                <sub_title>Cellulitis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="323"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="300"/>
              </event>
              <event>
                <sub_title>Fungaemia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="323"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="300"/>
              </event>
              <event>
                <sub_title>Pyelonephritis acute</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="323"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="300"/>
              </event>
              <event>
                <sub_title>Sepsis syndrome</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="323"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="300"/>
              </event>
              <event>
                <sub_title>Shunt infection</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="323"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="300"/>
              </event>
              <event>
                <sub_title>Sinusitis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="323"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="300"/>
              </event>
              <event>
                <sub_title>Subcutaneous abscess</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="323"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="300"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Injury, poisoning and procedural complications</title>
            <event_list>
              <event>
                <sub_title>Wound dehiscence</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="323"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="300"/>
              </event>
              <event>
                <sub_title>Femur fracture</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="323"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="300"/>
              </event>
              <event>
                <sub_title>Gastrointestinal anastomotic leak</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="323"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="300"/>
              </event>
              <event>
                <sub_title>Graft haemorrhage</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="323"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="300"/>
              </event>
              <event>
                <sub_title>Muscle strain</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="323"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="300"/>
              </event>
              <event>
                <sub_title>Accidental overdose</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="323"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="300"/>
              </event>
              <event>
                <sub_title>Hip fracture</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="323"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="300"/>
              </event>
              <event>
                <sub_title>Vascular graft occlusion</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="323"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="300"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Investigations</title>
            <event_list>
              <event>
                <sub_title>Blood glucose abnormal</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="323"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="300"/>
              </event>
              <event>
                <sub_title>Blood phosphorus decreased</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="323"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="300"/>
              </event>
              <event>
                <sub_title>Blood uric acid increased</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="323"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="300"/>
              </event>
              <event>
                <sub_title>Lymphocyte count decreased</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="323"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="300"/>
              </event>
              <event>
                <sub_title>White blood cell count decreased</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="323"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="300"/>
              </event>
              <event>
                <sub_title>Alanine aminotransferase increased</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="323"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="300"/>
              </event>
              <event>
                <sub_title>Aspartate aminotransferase increased</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="323"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="300"/>
              </event>
              <event>
                <sub_title>Blood calcium decreased</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="323"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="300"/>
              </event>
              <event>
                <sub_title>Blood calcium increased</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="323"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="300"/>
              </event>
              <event>
                <sub_title>Blood phosphorus abnormal</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="323"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="300"/>
              </event>
              <event>
                <sub_title>Blood sodium decreased</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="323"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="300"/>
              </event>
              <event>
                <sub_title>Blood urea abnormal</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="323"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="300"/>
              </event>
              <event>
                <sub_title>Blood uric acid abnormal</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="323"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="300"/>
              </event>
              <event>
                <sub_title>International normalised ratio increased</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="323"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="300"/>
              </event>
              <event>
                <sub_title>Liver function test abnormal</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="323"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="300"/>
              </event>
              <event>
                <sub_title>Neutrophil count decreased</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="323"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="300"/>
              </event>
              <event>
                <sub_title>Platelet count decreased</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="323"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="300"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Metabolism and nutrition disorders</title>
            <event_list>
              <event>
                <sub_title>Hypokalaemia</sub_title>
                <counts group_id="E1" subjects_affected="4" subjects_at_risk="323"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="300"/>
              </event>
              <event>
                <sub_title>Dehydration</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="323"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="300"/>
              </event>
              <event>
                <sub_title>Hyperglycaemia</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="323"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="300"/>
              </event>
              <event>
                <sub_title>Hyponatraemia</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="323"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="300"/>
              </event>
              <event>
                <sub_title>Hyperuricaemia</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="323"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="300"/>
              </event>
              <event>
                <sub_title>Failure to thrive</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="323"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="300"/>
              </event>
              <event>
                <sub_title>Hyperkalaemia</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="323"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="300"/>
              </event>
              <event>
                <sub_title>Hypocalcaemia</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="323"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="300"/>
              </event>
              <event>
                <sub_title>Malnutrition</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="323"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="300"/>
              </event>
              <event>
                <sub_title>Metabolic acidosis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="323"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="300"/>
              </event>
              <event>
                <sub_title>Hypoglycaemia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="323"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="300"/>
              </event>
              <event>
                <sub_title>Hypophosphataemia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="323"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="300"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Musculoskeletal and connective tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Pain in extremity</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="323"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="300"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Neoplasms benign, malignant and unspecified (incl cysts and polyps)</title>
            <event_list>
              <event>
                <sub_title>Endometrial cancer</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="323"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="300"/>
              </event>
              <event>
                <sub_title>Lung cancer metastatic</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="323"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="300"/>
              </event>
              <event>
                <sub_title>Acute myeloid leukaemia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="323"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="300"/>
              </event>
              <event>
                <sub_title>Adrenal gland cancer metastatic</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="323"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="300"/>
              </event>
              <event>
                <sub_title>Lymphoproliferative disorder</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="323"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="300"/>
              </event>
              <event>
                <sub_title>Renal cell carcinoma stage unspecified</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="323"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="300"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>Coma</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="323"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="300"/>
              </event>
              <event>
                <sub_title>Syncope</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="323"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="300"/>
              </event>
              <event>
                <sub_title>Cerebrovascular accident</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="323"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="300"/>
              </event>
              <event>
                <sub_title>Convulsion</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="323"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="300"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Pregnancy, puerperium and perinatal conditions</title>
            <event_list>
              <event>
                <sub_title>Intra-uterine death</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="323"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="300"/>
              </event>
              <event>
                <sub_title>Pregnancy</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="323"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="300"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Psychiatric disorders</title>
            <event_list>
              <event>
                <sub_title>Mental status changes</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="323"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="300"/>
              </event>
              <event>
                <sub_title>Confusional state</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="323"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="300"/>
              </event>
              <event>
                <sub_title>Affective disorder</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="323"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="300"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Renal and urinary disorders</title>
            <event_list>
              <event>
                <sub_title>Renal failure</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="323"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="300"/>
              </event>
              <event>
                <sub_title>Renal failure acute</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="323"/>
                <counts group_id="E2" subjects_affected="4" subjects_at_risk="300"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Respiratory, thoracic and mediastinal disorders</title>
            <event_list>
              <event>
                <sub_title>Dyspnoea</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="323"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="300"/>
              </event>
              <event>
                <sub_title>Respiratory failure</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="323"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="300"/>
              </event>
              <event>
                <sub_title>Pneumonia aspiration</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="323"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="300"/>
              </event>
              <event>
                <sub_title>Pulmonary oedema</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="323"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="300"/>
              </event>
              <event>
                <sub_title>Hypoxia</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="323"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="300"/>
              </event>
              <event>
                <sub_title>Pleural effusion</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="323"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="300"/>
              </event>
              <event>
                <sub_title>Respiratory disorder</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="323"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="300"/>
              </event>
              <event>
                <sub_title>Chronic obstructive pulmonary disease</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="323"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="300"/>
              </event>
              <event>
                <sub_title>Haemopneumothorax</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="323"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="300"/>
              </event>
              <event>
                <sub_title>Pulmonary embolism</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="323"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="300"/>
              </event>
              <event>
                <sub_title>Respiratory distress</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="323"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="300"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Vascular disorders</title>
            <event_list>
              <event>
                <sub_title>Deep vein thrombosis</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="323"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="300"/>
              </event>
              <event>
                <sub_title>Haemorrhage</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="323"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="300"/>
              </event>
              <event>
                <sub_title>Arterial occlusive disease</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="323"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="300"/>
              </event>
              <event>
                <sub_title>Hypotension</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="323"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="300"/>
              </event>
              <event>
                <sub_title>Vena cava thrombosis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="323"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="300"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>2</frequency_threshold>
        <default_vocab>MedDRA 10.0</default_vocab>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="195" subjects_at_risk="323"/>
                <counts group_id="E2" subjects_affected="187" subjects_at_risk="300"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Blood and lymphatic system disorders</title>
            <event_list>
              <event>
                <sub_title>Anaemia</sub_title>
                <counts group_id="E1" subjects_affected="7" subjects_at_risk="323"/>
                <counts group_id="E2" subjects_affected="10" subjects_at_risk="300"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Nausea</sub_title>
                <counts group_id="E1" subjects_affected="28" subjects_at_risk="323"/>
                <counts group_id="E2" subjects_affected="31" subjects_at_risk="300"/>
              </event>
              <event>
                <sub_title>Vomiting</sub_title>
                <counts group_id="E1" subjects_affected="14" subjects_at_risk="323"/>
                <counts group_id="E2" subjects_affected="18" subjects_at_risk="300"/>
              </event>
              <event>
                <sub_title>Diarrhoea</sub_title>
                <counts group_id="E1" subjects_affected="12" subjects_at_risk="323"/>
                <counts group_id="E2" subjects_affected="9" subjects_at_risk="300"/>
              </event>
              <event>
                <sub_title>Abdominal pain</sub_title>
                <counts group_id="E1" subjects_affected="7" subjects_at_risk="323"/>
                <counts group_id="E2" subjects_affected="9" subjects_at_risk="300"/>
              </event>
              <event>
                <sub_title>Constipation</sub_title>
                <counts group_id="E1" subjects_affected="4" subjects_at_risk="323"/>
                <counts group_id="E2" subjects_affected="10" subjects_at_risk="300"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>Oedema peripheral</sub_title>
                <counts group_id="E1" subjects_affected="17" subjects_at_risk="323"/>
                <counts group_id="E2" subjects_affected="13" subjects_at_risk="300"/>
              </event>
              <event>
                <sub_title>Pyrexia</sub_title>
                <counts group_id="E1" subjects_affected="16" subjects_at_risk="323"/>
                <counts group_id="E2" subjects_affected="16" subjects_at_risk="300"/>
              </event>
              <event>
                <sub_title>Chills</sub_title>
                <counts group_id="E1" subjects_affected="8" subjects_at_risk="323"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="300"/>
              </event>
              <event>
                <sub_title>Fatigue</sub_title>
                <counts group_id="E1" subjects_affected="6" subjects_at_risk="323"/>
                <counts group_id="E2" subjects_affected="6" subjects_at_risk="300"/>
              </event>
              <event>
                <sub_title>Pain</sub_title>
                <counts group_id="E1" subjects_affected="5" subjects_at_risk="323"/>
                <counts group_id="E2" subjects_affected="6" subjects_at_risk="300"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>Urinary tract infection</sub_title>
                <counts group_id="E1" subjects_affected="12" subjects_at_risk="323"/>
                <counts group_id="E2" subjects_affected="12" subjects_at_risk="300"/>
              </event>
              <event>
                <sub_title>Pneumonia</sub_title>
                <counts group_id="E1" subjects_affected="8" subjects_at_risk="323"/>
                <counts group_id="E2" subjects_affected="6" subjects_at_risk="300"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Injury, poisoning and procedural complications</title>
            <event_list>
              <event>
                <sub_title>Fall</sub_title>
                <counts group_id="E1" subjects_affected="5" subjects_at_risk="323"/>
                <counts group_id="E2" subjects_affected="6" subjects_at_risk="300"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Metabolism and nutrition disorders</title>
            <event_list>
              <event>
                <sub_title>Hypokalaemia</sub_title>
                <counts group_id="E1" subjects_affected="24" subjects_at_risk="323"/>
                <counts group_id="E2" subjects_affected="22" subjects_at_risk="300"/>
              </event>
              <event>
                <sub_title>Dehydration</sub_title>
                <counts group_id="E1" subjects_affected="9" subjects_at_risk="323"/>
                <counts group_id="E2" subjects_affected="6" subjects_at_risk="300"/>
              </event>
              <event>
                <sub_title>Hypomagnesaemia</sub_title>
                <counts group_id="E1" subjects_affected="9" subjects_at_risk="323"/>
                <counts group_id="E2" subjects_affected="5" subjects_at_risk="300"/>
              </event>
              <event>
                <sub_title>Hyperkalaemia</sub_title>
                <counts group_id="E1" subjects_affected="6" subjects_at_risk="323"/>
                <counts group_id="E2" subjects_affected="9" subjects_at_risk="300"/>
              </event>
              <event>
                <sub_title>Hyponatraemia</sub_title>
                <counts group_id="E1" subjects_affected="5" subjects_at_risk="323"/>
                <counts group_id="E2" subjects_affected="7" subjects_at_risk="300"/>
              </event>
              <event>
                <sub_title>Hypoglycaemia</sub_title>
                <counts group_id="E1" subjects_affected="4" subjects_at_risk="323"/>
                <counts group_id="E2" subjects_affected="8" subjects_at_risk="300"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Musculoskeletal and connective tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Arthralgia</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="323"/>
                <counts group_id="E2" subjects_affected="6" subjects_at_risk="300"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>Headache</sub_title>
                <counts group_id="E1" subjects_affected="14" subjects_at_risk="323"/>
                <counts group_id="E2" subjects_affected="20" subjects_at_risk="300"/>
              </event>
              <event>
                <sub_title>Dizziness</sub_title>
                <counts group_id="E1" subjects_affected="4" subjects_at_risk="323"/>
                <counts group_id="E2" subjects_affected="12" subjects_at_risk="300"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Psychiatric disorders</title>
            <event_list>
              <event>
                <sub_title>Insomnia</sub_title>
                <counts group_id="E1" subjects_affected="9" subjects_at_risk="323"/>
                <counts group_id="E2" subjects_affected="5" subjects_at_risk="300"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Renal and urinary disorders</title>
            <event_list>
              <event>
                <sub_title>Renal failure acute</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="323"/>
                <counts group_id="E2" subjects_affected="6" subjects_at_risk="300"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Respiratory, thoracic and mediastinal disorders</title>
            <event_list>
              <event>
                <sub_title>Dyspnoea</sub_title>
                <counts group_id="E1" subjects_affected="9" subjects_at_risk="323"/>
                <counts group_id="E2" subjects_affected="11" subjects_at_risk="300"/>
              </event>
              <event>
                <sub_title>Cough</sub_title>
                <counts group_id="E1" subjects_affected="7" subjects_at_risk="323"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="300"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Skin and subcutaneous tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Rash</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="323"/>
                <counts group_id="E2" subjects_affected="9" subjects_at_risk="300"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Vascular disorders</title>
            <event_list>
              <event>
                <sub_title>Hypotension</sub_title>
                <counts group_id="E1" subjects_affected="6" subjects_at_risk="323"/>
                <counts group_id="E2" subjects_affected="7" subjects_at_risk="300"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>The only disclosure restriction on the PI is that the sponsor can review results communications prior to public release and can embargo communications regarding trial results for a period that is less than or equal to 60 days. The sponsor cannot require changes to the communication and cannot extend the embargo.</restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Senior Vice President, Global Clinical Development</name_or_title>
      <organization>Merck Sharp &amp; Dohme Corp.</organization>
      <phone>1-800-672-6372</phone>
      <email>ClinicalTrialsDisclosure@merck.com</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

